/AGN.CN

AGN.CN Stock - Algernon Pharmaceuticals Inc.

Q: What is the analyst price target for AGN.CN?

Analyst price target information is not currently available for AGN.CN.

Q: What is AGN.CN's market cap?

Market capitalization information is not currently available for AGN.CN.

Healthcare|Biotechnology|CNQ

$0.08+0.00%

+$0.00 (+0.00%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.09

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for AGN.CN

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.40

52W High$0.12

52W Low$0.06

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	$-26,562	$-50,398	$-34,936	N/A	N/A
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Income	$-2,412,042	$-5,018,055	$-6,117,631	$-9,840,843	$-9,396,664
Net Income	$-502,982	$-6,781,200	$-6,054,356	$-7,734,080	$-8,538,207
Net Margin	N/A	N/A	N/A	N/A	N/A
EPS	$-0.03	$-0.45	$-0.87	$-1.04	$-2.03

Company Overview

Algernon Pharmaceuticals Inc. operates as a clinical stage pharmaceutical development company. It focuses on the areas of nonalcoholic steatohepatitis, chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cough, and acute lung injury associated with COVID-19 in Canada and Australia. The company's lead candidate is NP-120, an N-methyl-d-aspartate (NMDA) receptor glutamate receptor antagonist, which targets NMDA-type subunit 2B (Glu2NB), as well as exhibits agonist activity for the Sigma-1 receptor, a chaperone protein up-regulated during endoplasmic reticulum stress. It is also developing AP-188, a psychedelic compound that is part of the tryptamine family for the treatment of ischemic stroke in humans. Algernon Pharmaceuticals Inc. has an agreement with Charles River Laboratories for preclinical studies of AP-188 for the company's stroke clinical research program. Algernon Pharmaceuticals Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.

Visit Website

Earnings History & Surprises

AGN.CN

Beat Rate

78%

Last 9 quarters

Avg Surprise

+70.8%

EPS vs Estimate

Beats / Misses

7/2

Last 12 quarters

Latest EPS

$-0.01

Q2 2025

EPS Surprise History

Q2 23

-18.2%

$-0.13vs$-0.11

Q3 23

+23.9%

$-0.10vs$-0.13

Q4 23

+55.1%

$-0.08vs$-0.19

Q1 24

No data

Q2 24

No data

Q3 24

No data

Q1 25

No data

Q2 25

No data

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	Apr 27, 2026	—	—	—	—
Q1 2026	Jan 27, 2026	—	—	—	—
Q3 2025	Jul 30, 2025	—	—	—	—
Q2 2025	Apr 29, 2025	—	$-0.01	—	—
Q1 2025	Jan 29, 2025	—	$-0.01	—	—
Q4 2024	Dec 23, 2024	—	—	—	—
Q3 2024	Jul 29, 2024	—	$0.06	—	—
Q2 2024	Apr 29, 2024	—	$-0.05	—	—
Q1 2024	Jan 25, 2024	—	$-0.03	—	—
Q4 2023	Dec 29, 2023	$-0.19	$-0.08	+55.1%	✓ BEAT
Q3 2023	Jul 28, 2023	$-0.13	$-0.10	+23.9%	✓ BEAT
Q2 2023	May 1, 2023	$-0.11	$-0.13	-18.2%	✗ MISS
Q1 2023	Jan 31, 2023	$-0.16	$-0.20	-25.0%	✗ MISS
Q4 2022	Nov 26, 2022	$-0.17	$0.30	+276.5%	✓ BEAT
Q3 2022	Jul 29, 2022	$-0.23	$0.12	+152.2%	✓ BEAT
Q2 2022	Apr 27, 2022	—	$-0.23	—	—
Q1 2022	Jan 27, 2022	—	$-0.15	—	—
Q4 2021	Nov 26, 2021	$-0.75	$-0.08	+89.3%	✓ BEAT
Q3 2021	Jul 30, 2021	$-0.50	$-0.25	+50.0%	✓ BEAT
Q2 2021	Apr 30, 2021	$-0.75	$-0.50	+33.3%	✓ BEAT

Frequently Asked Questions about AGN.CN

What is AGN.CN's current stock price?

Algernon Pharmaceuticals Inc. (AGN.CN) is currently trading at $0.08 per share. The stock has moved +0.00% today.

What is the analyst price target for AGN.CN?

No analyst price targets are currently available for this stock.

What sector is Algernon Pharmaceuticals Inc. in?

Algernon Pharmaceuticals Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the CNQ exchange.

What is AGN.CN's market cap?

Algernon Pharmaceuticals Inc. has a market capitalization of $0.00 billion, making it a small-cap company.

Does AGN.CN pay dividends?

No, Algernon Pharmaceuticals Inc. does not currently pay a dividend to shareholders.